Trial · NCT07059377
Semaglutide for Smoking Cessation in Patients With Diabetes
NCT07059377, Phase 3, Recruiting, Ottawa Heart Institute Research Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Semaglutide for Smoking Cessation in Patients With Diabetes. Trials, record NCT07059377. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07059377
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Semaglutide for Smoking Cessation in Patients With Diabetes
- NCT number
- NCT07059377
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Conditions
- Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
- Interventions
- Semaglutide, Nicotine replacement
- First posted
- 2025-07-10
- Last updated
- 2026-09-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Project success | 12 months | Feasibility will be assessed to provide insights into the potential for a larger trial. Successful completion of this pilot will indicate that a full-scale study is both viable and likely to yield meaningful results. To measure this, the total number of people enrolled will be compared to the total number of people approached to participate. |
| Secondary | Smoking status | 6 months | Participants will be asked if they have quit smoking cigarettesat the 6-month follow-up. This will demonstrate the effectiveness of the pharmacotherapy and GLP-1 products. |
| Secondary | Blood glucose score | 6, and 12 months | The A1c test result is reported as a percentage. The score represents the portion of hemoglobin proteins that are holding glucose. The higher the percentage, the higher blood sugar level an individual has. The range of scores are \<5.7% to \>10%. Less than 5.7% means no diabetes,5.7% to 6.4% signals prediabetes. 6.5% or higher usually indicates Type 2 diabetes. HbA1c will be measured at 6 and 12 months in order to measure glycemic control. |
| Secondary | Height | 6, and 12 months | Height will be measured to look for change over time in both groups. It will be recorded in cm. |
| Secondary | Weight | 6, and 12 months | Height will be measured to look for change over time in both groups. It will be recorded in kgs. |
| Secondary | Waist circumference | 6, and 12 months | Height will be measured to look for change over time in both groups. It will be recorded in cm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07059377
GET https://conductscience.org/api/trials/v1/NCT07059377/registered